Navigation Links
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Date:1/7/2008

ore than six months.

To date, five dose-limiting toxicities (DLTs) have been reported, including Grade 3 palmar/plantar erythema (hand-foot syndrome), Grade 3 AST elevation, Grade 3 ALT elevation, and Grade 3 lipase elevation in patients dosed at 11.52 mg/kg (intermittent dosing schedule), as well as a DLT of Grade 2 mucositis in a patient dosed at 265 mg (daily dosing schedule). Serious adverse events (AEs) considered possibly or probably related to XL184 include one report each of Grade 3 fatigue and Grade 3 pulmonary embolism. Dose escalation continues in order to determine a maximum tolerated dose (MTD).

About XL184

XL184 is a novel, orally administered, small molecule anticancer compound that in preclinical models has demonstrated potent inhibition of both MET and VEGFR2. XL184 has also exhibited potent inhibition of other important receptor tyrosine kinases (RTKs) that have been implicated in various forms of cancer including RET, KIT, FLT3, and TIE2. In preclinical efficacy studies, XL184 has inhibited tumor growth and induced the regression of large tumors in a broad range of human tumor xenograft models including breast cancer, lung cancer and glioma. In laboratory studies, XL184 has demonstrated good oral bioavailability and pharmacokinetic properties.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Com
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
2. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
3. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
4. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
8. GlaxoSmithKline Accelerates Review of Exelixis XL880
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
11. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015  Rigrodsky & Long, P.A.: , ... ASPX )? , Did you purchase any of ... you think the proposed buyout price is too low? ... Rigrodsky & Long, P.A. announces that it ... of Auspex Pharmaceuticals, Inc. ("Auspex" or the "Company") (NASDAQ GM: ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... addition of the "Marine Biotechnology - Global ... Annual estimates and forecasts are provided ... seven-year historic analysis is provided for these markets. ... and secondary research. This report analyzes ...
(Date:3/30/2015)... 2015  Cochlear Corporation Vice President of U.S. ... to join Valencia Technologies ( www.valenciatechnologies.com ) and ... , who is the CEO of Valencia.  Schloffman ... will be responsible for generating enthusiasm and support ... coin-sized neuromodulation device in the treatment of ...
Breaking Medicine Technology:AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 2Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 2Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 3Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 4Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 5Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 7Cochlear VP of U.S. Sales Jerry Schloffman Accepts Chief of Market Development Position at Valencia Technologies 2
... Dec. 15, 2011 Medical Product Outsourcing ... Costa Rica (an MPO Symposium), March 19-21 at ... now for this high-power conference, consisting of networking, interactive ... Registration for this event will open in early January. ...
... sciences startup  PhotOral™  announced today it has licensed ... to develop a novel intraoral device that ... harmful dental plaque microorganisms. The agreement ... addressing the $7 billion oral care market.  PhotOral ...
Cached Medicine Technology:Medical Device Costa Rica: An MPO Symposium Helps Firms Connect, Learn & Master Global Manufacturing Skills 2Life Sciences Startup PhotOral Licenses Patented Oral Blue-Light Technology From Forsyth Institute 2
(Date:3/30/2015)... Garden City, NY (PRWEB) March 31, 2015 ... Manager / Co-Founder of Safe Hands Warm Hearts, ... is recognized with this prestigious distinction for leadership in ... women in the country, spanning virtually every industry and ... a powerfully vibrant networking community with nearly 700,000 members ...
(Date:3/30/2015)... Diego, CA (PRWEB) March 30, 2015 ... is proud to announce the start of its 41st ... bestselling author Jane McGonigal, and former Congressman Patrick J. ... Recovery Conference being held in San Diego, CA, ... Del Coronado. The national conference brings together leading experts ...
(Date:3/30/2015)... Pass, OR (PRWEB) March 30, 2015 ... and other drought stricken areas are scrambling to make ... Kleyne would those individuals to be aware that when ... can also lose water and become dehydrated. Kleyne calls ... it. , Kleyne talked about weather, body drought ...
(Date:3/30/2015)... Houston, Texas (PRWEB) March 30, 2015 Health ... 1 Fitness Trainer in the World Samir Becic, has created ... of State 2015 , which recognizes the world’s fittest leaders ... is the first and only list of its kind to ... and prime ministers. , Among the world leaders profiled on ...
(Date:3/30/2015)... 2015 In its 2015 survey of ... & Morton sixth among the top general contractors in ... has specialized in healthcare construction for more than half ... Morton ranked on the list with $657 million in ... built 2.6 million square feet with 82 percent of ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Rachel L. Gregus, Manager / Co-Founder of Safe Hands Warm Hearts, a 2015 Professional Woman of the Year 2Health News:Foundations Recovery Network Kicks Off Its 41st National Conference Specializing in the Treatment of Substance Abuse and Behavioral Health 2Health News:As California Dry Season Approaches, Risk of Body Drought Increases, Warns Fresh Water Advocate 2Health News:As California Dry Season Approaches, Risk of Body Drought Increases, Warns Fresh Water Advocate 3Health News:The Top 13 Fittest Heads of State: Why Putin Might Be No. 1 in Health and Fitness 2Health News:Modern Healthcare Ranks Robins & Morton No. 6 Contractor 2
... About Dangers of Medicating Children, Fleming ... Cold Prevention Strategies, ST. LOUIS, Sept. 19 ... the U.S. Food and Drug,Administration for use with young ... parents to help prevent their,children from catching colds in ...
... If you,ve been experiencing watery,eyes and excessive sneezing, ... the U.S., with an estimated 50 million Americans suffering. ... tune of 3 billion,dollars a year, often without knowing ... blood tests, the latest generation of,allergy tests, can help ...
... finds , WEDNESDAY, Sept. 19 (HealthDay News) -- If the ... is too quiet, it could mean that they,re being suppressed ... researchers warn. , A team at the University of Toledo, ... cells collected via bronchoscopy could help identify people genetically at ...
... Vaccine supplies are plentiful this year, but inoculation rates ... News) -- Too many Americans aren,t getting vaccinated for ... children and health-care workers -- U.S. health officials warned ... vaccine, we are still failing to protect a large ...
... are to be injected into those with cancer to ... of Medicine in Winston-Salem, North Carolina, and his colleagues ... Administration (FDA) to screen people for their ability to ... fighters will be given to cancer patients, after being ...
... will,have access to high-quality, evidence-based care for behavioral ... Senate. The,"Mental Health Parity Act of 2007" would ... provide parity with respect to all financial,requirements and ... ) "AHIP applauds the Senate for coming ...
Cached Medicine News:Health News:Countering Colds With Common Sense 2Health News:Countering Colds With Common Sense 3Health News:Hushed Genes Might Mean Higher Lung Cancer Risk 2Health News:More Americans Urged to Get Flu Shots 2Health News:More Americans Urged to Get Flu Shots 3Health News:Their immune cells, fighting your cancer 2
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTC/1Q chairs are recommended for the ... room, static control, health care and ...
Medicine Products: